The New England journal of medicine, 2018-06, Vol.378 (24), p.2288-2301
- Socinski, Mark A
- Jotte, Robert M
- Cappuzzo, Federico
- Orlandi, Francisco
- Stroyakovskiy, Daniil
- Nogami, Naoyuki
- Rodríguez-Abreu, Delvys
- Moro-Sibilot, Denis
- Thomas, Christian A
- Barlesi, Fabrice
- Finley, Gene
- Kelsch, Claudia
- Lee, Anthony
- Coleman, Shelley
- Deng, Yu
- Shen, Yijing
- Kowanetz, Marcin
- Lopez-Chavez, Ariel
- Sandler, Alan
- Reck, Martin
2018
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Socinski, Mark A
- Jotte, Robert M
- Cappuzzo, Federico
- Orlandi, Francisco
- Stroyakovskiy, Daniil
- Nogami, Naoyuki
- Rodríguez-Abreu, Delvys
- Moro-Sibilot, Denis
- Thomas, Christian A
- Barlesi, Fabrice
- Finley, Gene
- Kelsch, Claudia
- Lee, Anthony
- Coleman, Shelley
- Deng, Yu
- Shen, Yijing
- Kowanetz, Marcin
- Lopez-Chavez, Ariel
- Sandler, Alan
- Reck, Martin
- Titel
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- Ist Teil von
- The New England journal of medicine, 2018-06, Vol.378 (24), p.2288-2301
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2018
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- The addition of atezolizumab (anti–PD-L1 antibody) to a platinum-based chemotherapy regimen improved progression-free survival among patients who had not previously received chemotherapy for metastatic NSCLC, regardless of PD-L1 expression and EGFR or ALK genomic alteration status.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1716948Titel-ID: cdi_proquest_journals_2070387156
- Format
- –
- Schlagworte
- Aged, Anaplastic Lymphoma Kinase, Antibodies, Monoclonal - administration & dosage, Antibodies, Monoclonal - adverse effects, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Apoptosis, B7-H1 Antigen - antagonists & inhibitors, Bevacizumab, Bevacizumab - administration & dosage, Cancer therapies, Carboplatin, Carboplatin - administration & dosage, Carcinoma, Non-Small-Cell Lung - drug therapy, Carcinoma, Non-Small-Cell Lung - genetics, Carcinoma, Non-Small-Cell Lung - mortality, Carcinoma, Non-Small-Cell Lung - secondary, Chemotherapy, Death, Epidermal growth factor receptors, Female, Genes, erbB-1, Genotypes, Humans, Immunosuppression, Immunotherapy, Liver, Lung cancer, Lung Neoplasms - drug therapy, Lung Neoplasms - mortality, Lung Neoplasms - pathology, Lymphocytes T, Male, Medical prognosis, Metastases, Metastasis, Middle Aged, Monoclonal antibodies, Motivation, Mutation, Neoplasm Metastasis - drug therapy, Non-small cell lung carcinoma, Oncology, Paclitaxel, Paclitaxel - administration & dosage, Patients, PD-L1 protein, Population, Receptor Protein-Tyrosine Kinases - genetics, Survival Analysis, Targeted cancer therapy, Tumors, Vascular endothelial growth factor, Vascular Endothelial Growth Factor A - antagonists & inhibitors